Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis.

Abstract

The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing tenofovir treatment were the lowest. Patients treated with telbivudine had the highest one-month survival rate. Patients receiving enticavir therapy showed the lowest HBV DNA level. Our results indicate that tenofovir may be the best therapy for the treatment of HBV-related liver failure compared to other nucleoside analogues (including lamivudine, entecavir and telbivudine) and non-NAs treatment.

• Authors: Jian Wu, Fang Yin, Xinmin Zhou
• Journal: Acta pharmaceutica (Zagreb, Croatia) (Acta Pharm) Vol. 68 Issue 1 Pg. 19-30 (Mar 01 2018) ISSN: 1846-9558 [Electronic] Poland
• PMID: 29453915 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Antiviral Agents
• Nucleosides

Topics

• Antiviral Agents (therapeutic use)
• Hepatitis B virus (drug effects)
• Humans
• Liver Failure (drug therapy, virology)
• Network Meta-Analysis
• Nucleosides (therapeutic use)
• Treatment Outcome